US Stock Insider Trading | Schrodinger disclosed one insider transaction on February 11

K-LinePoet · 2026-02-22T21:11:20+00:00

On February 11, 2026, Schrodinger (SDGR) disclosed an insider trading transaction. Executive Abel Robert Lorne sold 1,230 shares on February 9, 2026.【Recent Insider Trading】| Disclosure Date | Position | Name | Transaction Date | Buy/Sell | Quantity | Price per Share/USD | Total Amount/USD || --- | --- | --- | --- | --- | --- | --- | --- || February 11, 2026 | Executive | Abel Robert Lorne | February 9, 2026 | Sell | 1230 | 13.51 | $16,600 || 2025

K-LinePoet

2026-02-22 21:11:20

On February 11, 2026, Schrödinger (SDGR) disclosed an insider transaction. Executive Abel Robert Lorne sold 1,230 shares on February 9, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 11, 2026	Executive	Abel Robert Lorne	February 9, 2026	Sell	1230	13.51	$16,600
October 17, 2025	Executive	Dugan Margaret	October 16, 2025	Sell	1395	21.07	$29,400
April 15, 2025	Executive	Akinsanya Karen	April 14, 2025	Buy	3345	2.92	$9,767.40
April 15, 2025	Executive	Akinsanya Karen	April 14, 2025	Sell	3345	25.00	$83,600
April 15, 2025	Executive	Akinsanya Karen	April 14, 2025	Sell	5000	25.11	$125,600
April 15, 2025	Executive	Akinsanya Karen	April 14, 2025	Sell	8378	25.11	$210,400
April 15, 2025	Executive	Akinsanya Karen	April 14, 2025	Buy	13,400	3.22	$43,100
March 7, 2025	Executive	Herman Jenny	March 6, 2025	Sell	666	21.11	$21,100
March 4, 2025	Executive	Porges Geoffrey Craig	March 3, 2025	Sell	5491	21.76	$119,500
February 19, 2025	Executive	Tran Yvonne	February 18, 2025	Buy	3902	4.34	$16,900

[Company Information]

Schrödinger, Inc. was incorporated in California in August 1990 under applicable laws. The company has developed a physics-based computational platform capable of accurately predicting key properties of molecules, enabling the discovery of high-quality, novel molecules for drug development and materials applications at lower costs and faster speeds. Their software is used by biopharmaceutical, industrial companies, academic institutions, and government laboratories worldwide. The company is a leading provider of computational software solutions for drug discovery. In addition to offering various software solutions to accelerate all stages of molecule discovery, design, and optimization, they leverage their platform and capabilities through a series of collaborations and wholly owned drug discovery programs covering a broad range of disease targets and indications.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.